Tajikistan Liability for Concealment of Adverse Information: Article 20(4) Compliance Guide

1. Key takeaways

Article 20(4) qualifies three types of conduct directly as grounds for liability: concealing adverse reaction information, submitting incomplete adverse reaction information, and failing to take necessary measures, with liability determined under the legislation of the Republic of Tajikistan. GRZAN draws attention to a detail that is easily ignored: the subjects of liability under this paragraph are entities engaged in medical and pharmaceutical activity and registration certificate holders, and the word manufacturer does not appear in the text. However, read together with the reporting obligation of manufacturers under Article 20(3) and the withdrawal ground of Article 21(1)(5), manufacturers are not thereby released from liability; instead, they bear the consequences through the market withdrawal chain.

2. Legal basis

3. Expert insights

Insight 1: among the three types of conduct under Article 20(4), failure to take necessary measures is the most extensible. Concealment and incomplete submission are passive acts with relatively clear boundaries, whereas failure to take necessary measures is a demand for positive action, whose content includes recalls, warnings, revision of instructions for use, suspension notices and other measures. The GRZAN approach is to convert the list of necessary measures into a checklist and to retain decision records in internal processes.

Insight 2: the list of subjects of liability does not match Article 20(3), creating a mismatch between reporting duties and liability consequences. The reporting entities under paragraph 3 include manufacturers, while the subjects of liability under paragraph 4 do not. This mismatch should not be read as an exemption for manufacturers, because Article 21(1)(5) lists the failure of the registration certificate holder and the manufacturer to fulfill the obligation to monitor adverse reactions directly as a withdrawal ground. For manufacturers, the form of the consequence shifts from liability pursuit to loss of market access.

Insight 3: Article 20(5) makes foreign information an objective reference for determining concealment. The paragraph requires the supervisory authority, when making decisions on registration, re-registration, suspension and prohibition of use, to take into account vigilance and monitoring information obtained abroad. Its meaning is that if a product has already been flagged or withdrawn in another country on safety grounds while nothing has been reported locally, the determination of concealment can rest on comparable external evidence. This substantially lowers the evidentiary burden of the regulatory authority.

Insight 4: the information disclosure mechanism of Article 44(5) forms a reputational constraint alongside the liability provision. The paragraph requires disclosure of information on registration, cancellation and non-conformity. Once a withdrawal occurs, the information enters public channels, and its impact extends beyond a single product.

Insight 5: Article 48 provides residual liability. Natural persons and legal entities bear liability under the legislation of the Republic of Tajikistan for failure to comply with the requirements of the law. The combination of Article 20(4) and Article 48 means that liability targets both the specific conduct and the full range of obligations under the law.

4. Practical recommendations

1. Build a checklist of necessary measures and retain decision records. Under Article 20(4), convert recalls, warnings, revision of instructions for use, suspension notices and other measures into a checklist, and record every assessment and decision in writing.
2. Design the submission standard as complete rather than minimal. Under Article 20(4), incomplete submission is placed on a par with concealment; it is recommended that each report include the factual description, the assessment conclusion and the measures to be taken.
3. Manage foreign safety information in parallel. Under Article 20(5), establish a mechanism for collecting global safety information and synchronizing it locally, so that a case flagged abroad is never left unreported locally.
4. Include the withdrawal ground in the manufacturer risk register. Under Article 21(1)(5), manufacturers must maintain records of the adverse reaction monitoring obligation together with the registration certificate holder.
5. Monitor the disclosure channels of Article 44(5). Establish a periodic search mechanism for public information to promptly detect cancellation or non-conformity announcements relating to own products.

5. Verification checklist

• □ Confirmed that the three grounds for liability under Article 20(4) are concealment, incomplete submission and failure to take necessary measures
• □ Confirmed that the subjects of liability under Article 20(4) are entities engaged in medical and pharmaceutical activity and registration certificate holders
• □ Confirmed that manufacturers enter the withdrawal chain through Article 21(1)(5) rather than being exempt
• □ Established a checklist of necessary measures and retained decision records
• □ Designed report templates to the standard of complete submission
• □ Established a mechanism for collecting foreign safety information and synchronizing it locally (Article 20(5))
• □ Established a periodic search mechanism for public information under Article 44(5)

Regulatory information verified as of October 29, 2026.

In the Central Asia market, the core capabilities of GRZAN concentrate on three points. First, distinguishing the different legal positions of individual markets within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states, where a national pathway and a Union pathway both exist; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services, which may act as the statutory representative of manufacturers in these countries and assume registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com